Try our beta test site

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors (TRX518-001)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2015 by GITR, Inc.
Cancer Research Institute, New York City
Information provided by (Responsible Party):
GITR, Inc. Identifier:
First received: November 9, 2010
Last updated: November 18, 2015
Last verified: November 2015

TRX518-001 is an open label, non-randomized single group assignment, Phase 1 single dose escalation study in adults with biopsy proven unresectable Stage III or Stage IV melanoma or other solid tumor malignancies. The study objectives are to determine the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of TRX518 and to define the maximum tolerated dose at which there are tolerable side effects and/or maximum PK/PD parameter changes.

Subjects will be assigned to a cohort in the order screening is completed. Dose will depend upon the cohort in which a subject is enrolled and cohorts will be dosed consecutively by ascending dose.

MSKCC Study #10-147

Condition Intervention Phase
Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies
Biological: TRX518
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A First-in-Human Single Ascending Dose Study of TRX518 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies

Resource links provided by NLM:

Further study details as provided by GITR, Inc.:

Primary Outcome Measures:
  • 1. Adverse events (Safety) [ Time Frame: 18 weeks ]
    Any adverse change in health or side effect from the initiation of the study drug dose through completion or premature withdrawal.

  • 2. Pharmacokinetics (PK) [ Time Frame: 18 weeks ]
    Observations of the distribution, duration of effects and chemical changes of TRX518 in the body and the effects and routes of the body's elimination of TRX518.

  • 3. Pharmacodynamics (PD) [ Time Frame: 18 weeks ]
    Observation of the effects of TRX518 on the body and immune system.

Secondary Outcome Measures:
  • Observation of effects, if any, on circulating lymphoid cell number and function, TRX518 potential immunogenicity, and TRX518 long term safety as reflected by adverse event reports at 6 - 24 months after a single dose. [ Time Frame: 6, 12, 18, 24 months ]

Estimated Enrollment: 40
Study Start Date: October 2010
Estimated Study Completion Date: March 2016
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TRX518 Biological: TRX518
Humanized, Fc disabled, anti-human GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody

Detailed Description:

The following visits are required:

  • Screening visit: 1 to 2 appointments will be conducted to determine eligibility. All or most requirements can be determined from the patient's medical records.
  • Baseline visit: within 7 days of the planned study dosing day a baseline physical exam, blood tests and electrocardiogram will be obtained.
  • Dosing visit: 1 outpatient visit where TRX518 will be given IV over 1 hour followed by 4 hours of observation and some repeat blood tests.
  • Follow up visits: 5 outpatient visits following dosing at 1, 8 and 15 days and 3, 6, 12, and 18 weeks post dosing
  • Long term follow-up: 4 brief assessments by medical record review and/or telephone contact at 6, 12, 18, and 24 months post dosing.
  • The core study duration is 18 weeks. The follow-up study duration is 24 months.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years or older at the time of dose initiation.
  • Unresectable Stage III or Stage IV biopsy proven malignant melanoma or other solid tumor malignancies, with at least 1 measurable lesion, who have failed to respond to or relapsed following standard treatment or who have declined to pursue standard treatment, in otherwise stable health (as confirmed by medical history, physical examination, ECG, and screening laboratory tests).
  • Expected survival of at least 12 weeks after dosing.
  • Karnofsky Performance Status ≥70 in the 7 day baseline period immediately prior to dosing.
  • Evidence of adequate organ function by standard laboratory tests.
  • All female subjects of child bearing age must be either surgically sterile, postmenopausal for at least 1 year, or using an acceptable method of contraception. Adequate contraception for both male and female subjects must be used from the beginning of the screening period until at least 8 weeks after the last dose of TRX518.

Exclusion Criteria:

  • Evidence of progression of central nervous system (CNS) metastases or symptomatic CNS metastases within 30 days prior to dosing.
  • Ocular melanoma.
  • Any major surgery within 6 weeks prior to dosing.
  • Any history of antitumor therapy (standard or experimental) completed within 30 days prior to dosing.
  • Any concomitant serious physical illness other than cancer (i.e., immune deficiency disease, bleeding disorder, etc.) within 1 year prior to dosing. Specifically, no history of autoimmune disease.
  • Clinically significant heart disease, defined as NYHA Class III or IV.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01239134

United States, New York
Melanoma and Sarcoma Service / Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Ruth-Ann Roman    646-888-2395   
Principal Investigator: Jedd Wolchok, MD, PhD         
United States, Ohio
Siedman Cancer Center / University Hospitals of Cleveland Recruiting
Cleveland, Ohio, United States, 44106
Contact: Henry Koon, MD    216-844-3951   
Principal Investigator: Henry Koon, MD         
Taussig Cancer Institute / Cleveland Clinic Foundation Recruiting
Cleveland, Ohio, United States, 44195
Contact: Vamsidhar Velcheti, MD    216-444-8665   
Principal Investigator: Vamsidhar Velcheti, MD         
Sponsors and Collaborators
GITR, Inc.
Cancer Research Institute, New York City
Principal Investigator: Principle Investigator: Jedd Wolchok, MD, PhD Memorial Sloan Kettering Cancer Center
  More Information

Additional Information:
Responsible Party: GITR, Inc. Identifier: NCT01239134     History of Changes
Other Study ID Numbers: TRX518-001 
Study First Received: November 9, 2010
Last Updated: November 18, 2015

Keywords provided by GITR, Inc.:
Malignant melanoma
Stage III or Stage IV
Solid tumor

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas processed this record on February 24, 2017